XNAS · Healthcare · Biotechnology
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.78 | -0.74 | +5.13% | $1.7M | ✅ Beat | +0.00% | -9.99% | — |
| 2026-03-19 | Q4 2025 | -0.97 | -0.94 | +3.09% | $1.9M | ✅ Beat | -1.50% | +3.70% | -1.54% |
| 2025-11-13 |
| Q3 2025 |
| -0.97 |
| -1.06 |
| -9.28% |
| $2.1M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -1.28 | -1.27 | +0.78% | $2.7M | mixed | -1.81% | -0.23% | -1.13% |
| 2025-03-19 | Q4 2024 | -1.44 | -1.74 | -20.83% | $0 | ❌ Miss | -18.31% | +12.59% | +7.55% |
| 2024-11-13 | Q3 2024 | -4.50 | -1.73 | +61.56% | $0 | ✅ Beat | -12.95% | -10.82% | -22.39% |
| 2024-08-13 | Q2 2024 | — | -23.10 | — | $0 | — | +1.36% | +3.67% | -10.21% |
Showing last 7 quarters.